Nano24

Nano24 is a clinical stage company co-founded by Shapira and Arber. Nano24 developed a versatile platform solution, EXO-CD24, for the cytokine storm (CS), the main cause of death in the last 7/8 global pandemics and probably in the next one to come. 

The CS leads to ample of urgent unmet diseases with no medical therapy. 60M new cases annually and 15M deaths. EXO-CD24, genetically modified exosomes overexpressing CD24, is the first drug to distinguish between self and non-self. By selective suppression the host response to tissue injury-driven inflammation, it reverts the immune system back to normal activity, mitigating the CS without compromising pathogen clearance. Combination of two cutting-edge technologies: CD24(drug)-immunomodulator, smarter than steroids. Exosomes(carrier) small extracellular vesicles crucial for cell-cell communication. Administration by inhaler is a significant clinical advantage. EXO-CD24 can be given anywhere by anyone, even by the patient himself. It has promising efficacy and exceptional safety (no SAE/AE, with ~4Y F/U) in >220 patients.